BioSenic SA is a biotechnology company with extensive scientific and clinical experience in the field of orthopedics and regenerative therapies, specializing in the clinical development of therapies for bone and cartilage repair. BioSenic SA still holds stakes in its clinical assets ALLOB and JTA, but is now focusing on joint development with 4Moving Biotech of a GLP-1-based disease-modifying therapy for veterinary use, particularly for recovery after ligament surgery in dogs. BioSenic SA is also focusing on other potential new partnerships.

Employees

Sector

Pharmaceuticals

More about the company

Quotes

Date	Price	Change
26-09-11	€0.002000	0.00%
26-09-10	€0.002000	0.00%
26-09-09	€0.002000	0.00%
26-09-08	€0.002000	0.00%
26-09-07	€0.002000	0.00%

Real-time Euronext Bruxelles

More quotes

Annual profits - Rate of surprise

Company calendar

Market Closed - Euronext Bruxelles 11:55:00 2026-09-11 EDT			5-day change	1st Jan Change
0.002000 ^EUR	0.00%		0.00%	-13.04%

25-10-27	BioSenic S.A. Reports Earnings Results for the Half Year Ended June 30, 2025	CI
25-10-02	BioSenic S.A. Reports Earnings Results for the Full Year Ended December 31, 2024	CI

Market Cap	1.5M 1.74M 1.42M 1.29M 2.42M 166M 2.43M 16.89M 6.49M 84.71M 6.55M 6.4M 268M	P/E 2023	-0.29x	P/E 2024	-0.28x
Enterprise Value	28.84M 33.47M 27.31M 24.75M 46.43M 3.2B 46.67M 324M 125M 1.63B 126M 123M 5.14B	EV / Sales 2023	113x	EV / Sales 2024	286x
Free-Float	85.86%	Yield 2023 *	-	Yield 2024	-

Markets		Quality
Euronext Bruxelles	BIOS	Real-time
CBOE	0R55	Real-time
CBOE	BOTHEb	Real-time

25-10-27	BioSenic S.A. Reports Earnings Results for the Half Year Ended June 30, 2025	CI
25-10-02	BioSenic S.A. Reports Earnings Results for the Full Year Ended December 31, 2024	CI
25-09-28	Bone Therapeutics SA Reports Earnings Results for the Full Year Ended December 31, 2024	CI
24-10-28	BioSenic S.A. Announces Executive Changes	CI
24-09-30	BioSenic S.A. Reports Earnings Results for the Half Year Ended June 30, 2024	CI
24-09-29	Bone Therapeutics SA Reports Earnings Results for the Half Year Ended June 30, 2024	CI
24-09-17	BioSenic Deputy CEO Steps Down	MT
24-09-17	Véronique Pomi-Schneiter Step Down as BioSenic's Deputy CEO	CI
24-08-14	BioSenic Unit Secures European Patent for Multiple Sclerosis Treatment	MT
24-08-14	Medsenic, Subsidiary of Biosenic Receives the Intention to Grant Key European Patent from European Patent Office	CI
24-08-13	BioSenic Grants of A Key Patent by the Japan Patent Office to Expand Protection of the Arsenic Trioxide Platform	CI
24-07-18	Biosenic Releases New In-Depth Analysis of Its Positive Phase 2 Clinical Data for Optimal Administration Scheme for Its Next Late-Stage Trial of Arsenic Trioxide Targeting Cgvhd	CI
24-07-05	BioSenic Seeks US Patent Extension for Sepsis Drug	MT

BioSenic SA Stock

Stocks

BIOS

BE0974280126

Pharmaceuticals

Valuation : BioSenic SA

Chart: BioSenic SA

Latest news : BioSenic SA

Analysts' recommendations : BioSenic SA

Press Releases : BioSenic SA

News in other languages : BioSenic SA

Quotes and Performance

Price Extremes

Managers and Directors : BioSenic SA

Other Pharmaceuticals

Financials

Company Profile

Quotes

Annual profits - Rate of surprise

12-14	BioSenic : Report from Auditor on ESEF format 2024 Annual Report	PU
25-09-25	BioSenic : appoints CarKath SRL, represented by Mr Eric Halioua, as chairman of the board of directors	PU
25-08-29	BioSenic : provides an update on the preparation of the annual accounts and annual report for the financial year ending on 31 December 2024	PU
25-08-04	BioSenic : announces the homologation by the Enterprise Court of BioSenic's amicable agreements with five main creditors to restructure over €22 million of debt and appointment of two new independent directors	PU
25-07-01	BioSenic : announces partnership with 4Moving Biotech and secures its financing.	PU

05-07	BioSenic : Procuration pour l'actionnaire
05-07	BioSenic : Rapport annuel 2025
05-07	BioSenic : Communiqué de Presse - Convocation à l'Assemblée Générale Ordinaire
04-28	BioSenic : BIOS PR 2026 avril Denominator FR20260428
04-12	BioSenic : annonce l'émission de droits de souscription au bénéfice de membres du conseil d'administration

1 week	0		0
1 month	0		0
Current year	0		0
1 year	0		0
3 years	0		0.19
5 years	0		0.35
10 years	0		0.35

Director	Title	Age	Since
Jean-Luc Vandebroek BRD	Director/Board Member	55	2021-12-31
Eric Halioua CHM	Chairman	-	2025-08-31
Virginie Miath BRD	Director/Board Member	-	2026-01-28

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
BIOSENIC SA	0.00%	0.00%	-23.08%	-92.91%	1.52M
ELI LILLY AND COMPANY	-0.65%	-2.93%	+47.70%	+86.17%	994B
JOHNSON & JOHNSON	-0.29%	-3.51%	+49.15%	+62.35%	640B
ABBVIE INC.	+0.83%	+0.26%	+17.76%	+72.25%	454B
ROCHE HOLDING AG	-0.38%	-3.59%	+30.13%	+35.17%	337B
NOVARTIS AG	-0.09%	-13.54%	+13.34%	+24.95%	261B
ASTRAZENECA PLC	-0.43%	-2.48%	-0.73%	+9.58%	246B
AMGEN INC.	-1.34%	-13.70%	+36.53%	+44.96%	204B
NOVO NORDISK A/S	-3.44%	-7.51%	-20.63%	-59.44%	190B
GILEAD SCIENCES, INC.	-0.75%	-4.82%	+25.46%	+87.14%	178B
Average	-0.65%	-5.18%	+17.56%	+27.02%	350.48B
Weighted average by Cap.	-0.51%	-4.42%	+30.96%	+54.95%

	2023	2024
Net sales	336K 390K 318K 288K 541K 37.26M 544K 3.78M 1.45M 18.95M 1.46M 1.43M 59.89M	102K 118K 96.58K 87.54K 164K 11.31M 165K 1.15M 441K 5.75M 445K 435K 18.18M
Net income	-28.78M -33.4M -27.25M -24.7M -46.34M -3.19B -46.57M -324M -124M -1.62B -125M -123M -5.13B	-4.77M -5.53M -4.51M -4.09M -7.68M -529M -7.72M -53.62M -20.62M -269M -20.78M -20.33M -850M
Net Debt	28.04M 32.55M 26.55M 24.07M 45.15M 3.11B 45.38M 315M 121M 1.58B 122M 120M 5B	27.34M 31.73M 25.88M 23.46M 44.01M 3.03B 44.24M 307M 118M 1.54B 119M 117M 4.87B